JGJingyi Guo

Jingyi Guo

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Jingyi Guo has a total of 11 co-authors. Here are the top co-authors by number of shared publications:

  • Guangning Nie

    Department of Gynecology, The Second Affiliated Hospital of Guangzhou University of Chinese Medicine, Guangzhou 510120, China

    1 shared publication
  • Jiabing Chen

    Science and Technology Innovation Center, Guangzhou University of Chinese Medicine, Guangzhou, Guangdong 510080, China

    1 shared publication
  • Jiayu Li

    Science and Technology Innovation Center, Guangzhou University of Chinese Medicine, Guangzhou, Guangdong 510080, China

    1 shared publication
  • Jun Li

    State Key Laboratory of Dampness Syndrome of Chinese Medicine, the Second Affiliated Hospital of Guangzhou University of Chinese Medicine, Guangzhou, Guangdong 510120, China

    1 shared publication
  • Lei Wang

    Dongguan Hospital of Traditional Chinese Medicine, Guangzhou University of Chinese Medicine, Dongguan, China

    1 shared publication
  • Naihua Liu

    Science and Technology Innovation Center, Guangzhou University of Chinese Medicine, Guangzhou, Guangdong 510080, China

    1 shared publication

Latest Publications

  • Open Access

    Hepatic Clstn3 Ameliorates Lipid Metabolism Disorders in High Fat Diet-Induced NAFLD through Activation of FXR

    by Jingyi Guo, Shangyi Huang, Qincheng Yi, Naihua Liu, Tianqi Cui, Siwei Duan, Jiabing Chen, Jiayu Li, Jun Li, Lei Wang, et al.

    Non-alcoholic fatty liver disease (NAFLD) has becomeserious liverdisease all over the world. At present, NAFLD caused by high calorieand fat diet is increasing. Calsyntenin-3 (Clstn3) is a transmembraneprotein that has recently been found to participate in lipid energymetabolism. But whether Clstn3 affects NAFLD lipid metabolism hasnot been analyzed. We stimulate the mice primary hepatocytes (MPHs)with oleic acid and palmitic acid (OA & PA) to establish a cellmodel. Then, potential targets, including Clstn3 gene, were validatedfor improving lipid metabolism disorder in NAFLD model mice (HFD anddb/db) by silencing and overexpressing hepatic Clstn3. Moreover, theeffects of Clstn3 on lipid homeostasis were determined by functionaldetermination, triglyceride (TG) levels, total cholesterol (TC) levels,ELISA, and qRT-PCR detection. Our results displayed that Clstn3 wasdecreased in the NAFLD mice model. Also, overexpression of Clstn3improved lipid metabolism disorders, gluconeogenesis, and energy homeostasisand reduced liver injury, inflammation, and oxidative stress injury.However, opposite results were obtained in Clstn3-silencing mice,suggesting that the Clstn3 gene is closely related to lipid metabolismdisorder in NAFLD. RNAseq expression demonstrated that Farnesoid XReceptor (FXR) expression was increased after overexpression of Clstn3.Clstn3 supplementation in FXRKO mice can improve the dysfunction causedby insufficient FXR, suggesting that Clstn3 can improve the NAFLDlipid metabolism disorder to some extent through FXR, which may providea new method for the treatment of NAFLD.